Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00928070 · ClinicalTrials.gov registry record · Phase 4

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

A Phase 4 study, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
566
Enrollment target

NCT00928070 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 566 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00928070, a Phase 4 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
566 participants
Enrollment target

Study Summary

This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).

Interventions

  • DRUG Placebo
  • DRUG Fesoterodine

Trial Details

FieldValue
Enrollment Target 566 participants
Start Date 2009-09
Est. Completion 2011-09
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00928070

The ClinicalTrials.gov registry entry for NCT00928070 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 566 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00928070 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00928070 about?

NCT00928070 is a clinical study titled "A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder". This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).

What is the current status of trial NCT00928070?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 566 participants. The study started on 2009-09. Estimated completion is 2011-09.

What interventions are being tested in trial NCT00928070?

The interventions under investigation include: Placebo (DRUG), Fesoterodine (DRUG).

Who is sponsoring clinical trial NCT00928070?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.